Overview
In this interview with an Italian KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients. We discuss the KOL’s drug preferences and patient preferences within each class and the reasons behind these. The recent results of the PIONEER studies of oral semaglutide, and the increasing need for cardiovascular data for new drugs that treat type 2 diabetes are also discussed.
In this interview with an Italian KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients. We discuss the KOL’s drug preferences and patient preferences within each class and the reasons behind these. The recent results of the PIONEER studies of oral semaglutide, and the increasing need for cardiovascular data for new drugs that treat type 2 diabetes are also discussed.
